Add to calendar
Every year, 2,500 Australians are diagnosed with Myeloma, an incurable blood cancer. While patients undergo multiple rounds of chemoimmunotherapy to control their symptoms, most myeloma patients survive less than six years from their diagnosis.
Chimeric antigen receptor (CAR) T-cells that target B-cell maturation antigen (BCMA) protein on myeloma cells are a new and highly effective cellular therapy in patients who have exhausted all other treatment options.
Join Associate Professor Agnes Yong to learn about her team’s research aims to help Western Australian patients access this life-saving treatment at Royal Perth Hospital.